Sustained-release pharmaceutical composition for treating allergic rhinitis as well as preparation method and application thereof

A technology for allergic rhinitis and sustained-release drugs, which is applied in the directions of drug combination, drug delivery, pharmaceutical formulation, etc., can solve the problems of reduced efficacy, side effects of oral preparations, and inability of sprays to be sprayed into edema, so as to reduce drug resistance. , the effect of improving the curative effect

Pending Publication Date: 2019-11-22
马鹏飞
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Among them, in drug treatment, choosing a single glucocorticoid, antihistamine, antileukotriene, mast cell membrane stabilizer, decongestant, anticholinergic nasal spray, and oral treatment can relieve symptoms, but long-term use will lead to drug resistance and Reduce curative effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0022] Example 1

[0023] A sustained-release pharmaceutical composition for the treatment of allergic rhinitis, comprising the following raw materials in mass-volume concentrations: loratadine 0.5 mg / ml, cromolyn disodium 16 mg / ml, dexamethasone 0.1 mg / ml, hydrochloric acid Ephedrine 8mg / ml, levofloxacin 4mg / ml, and the sustained-release pharmaceutical composition also includes citric acid.

[0024] The sustained-release pharmaceutical composition further includes a film matrix, which includes a film material, a plasticizer, a surfactant, a porogen, and a solvent.

[0025] The film material is polyvinyl alcohol, hydroxypropyl cellulose, and hypromellose.

[0026] The plasticizer is glycerin.

[0027] The surfactant is polysorbate-80.

[0028] The porogen is polyethylene glycol.

[0029] The solvent is ethanol, water and acetone.

[0030] The preparation method of the slow-release pharmaceutical composition for treating allergic rhinitis includes the following steps:

[0031] 1) Weigh lora...

Example Embodiment

[0034] Example 2

[0035] A sustained-release pharmaceutical composition for the treatment of allergic rhinitis, comprising the following raw materials in mass-volume concentrations: loratadine 0.8 mg / ml, cromolyn disodium 20 mg / ml, dexamethasone 0.18 mg / ml, hydrochloric acid Ephedrine 11mg / ml, levofloxacin 5mg / ml, and the sustained-release pharmaceutical composition also includes citric acid.

[0036] The sustained-release pharmaceutical composition further includes a film matrix, which includes a film material, a plasticizer, a surfactant, a porogen, and a solvent.

[0037] The film material is povidone, methacrylate-methacrylic acid copolymer, and ethylene-vinyl acetate copolymer.

[0038] The plasticizer is propylene glycol.

[0039] The surfactant is sodium lauryl sulfate.

[0040] The porogen is polyethylene glycol.

[0041] The solvent is ethanol, water and acetone.

[0042] The preparation method of the slow-release pharmaceutical composition for treating allergic rhinitis include...

Example Embodiment

[0045] Example 3

[0046] A sustained-release pharmaceutical composition for the treatment of allergic rhinitis, comprising the following raw materials in mass-volume concentration: loratadine 1.2mg / ml, cromolyn disodium 23mg / ml, dexamethasone 0.25mg / ml, hydrochloric acid Ephedrine 15mg / ml, levofloxacin 7mg / ml, and the sustained-release pharmaceutical composition also includes citric acid.

[0047] The sustained-release pharmaceutical composition further includes a film matrix, which includes a film material, a plasticizer, a surfactant, a porogen, and a solvent.

[0048] The film material is ethyl cellulose.

[0049] The plasticizer is sorbitol.

[0050] The surfactant is soybean phospholipids.

[0051] The porogen is sodium chloride.

[0052] The solvent is ethanol, water and acetone.

[0053] The preparation method of the slow-release pharmaceutical composition for treating allergic rhinitis includes the following steps:

[0054] 1) Weigh loratadine, cromolyn disodium, dexamethasone, ep...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Thicknessaaaaaaaaaa
Thicknessaaaaaaaaaa
Thicknessaaaaaaaaaa
Login to view more

Abstract

The invention relates to the technical field of rhinitis treatment medicines, and particularly discloses a sustained-release pharmaceutical composition for treating allergic rhinitis. The sustained-release pharmaceutical composition is prepared from the following raw materials according to the mass-volume concentration: 0.5 to 1.2 mg/ml of loratadine, 16 to 23 mg/ml of disodium cromoglycate, 0.1 to 0.25 mg/ml of dexamethasone, 8 to 15 mg/ml of ephedrine hydrochloride and 4 to 7 mg/ml of levofloxacin. The invention also discloses a preparation method of the sustained-release pharmaceutical composition for treating allergic rhinitis. The invention also discloses an application of the sustained-release pharmaceutical composition for treating allergic rhinitis. Aiming at the defects of allergic rhinitis natural environment pathogenic factors, complex variability of body autoimmune conditions, single clinical medicine component, poor nasal cavity adhesion, low bioavailability and the like,the medicine is prepared into a compound preparation according to a certain proportion, and a film agent is prepared by using a slow release technology to treat allergic rhinitis, so that the bioavailability and the curative effect of the medicine are improved.

Description

technical field [0001] The invention relates to the technical field of drugs for treating rhinitis, in particular to a slow-release drug for treating allergic rhinitis, a preparation method and application. Background technique [0002] Allergic rhinitis (AR), also known as allergic rhinitis, is a common allergic reaction in clinical practice. Its typical symptoms are nasal congestion, runny nose, sneezing and / or nasal itching. It is related to the effect, and there are a large number of patients at present, and the treatment is recurrent, protracted and unhealed, and the curative effect is not good. [0003] Although allergic rhinitis cannot be completely cured yet, through standardized comprehensive prevention and treatment, the symptoms of patients can be well controlled and the quality of life can be significantly improved. At present, the prevention and treatment of allergic rhinitis includes allergen avoidance, drug treatment and immune Three kinds of treatment: aller...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/573A61K47/12A61P11/02A61P37/08A61K31/137A61K31/352A61K31/4545A61K31/5383
CPCA61K31/4545A61K31/352A61K31/573A61K31/137A61K31/5383A61K9/0043A61K47/12A61P11/02A61P37/08A61K2300/00
Inventor 马鹏飞童红霞盛喜霞张莉李毅高翔杨若朦王莉芳王袖和王红王雁王燕冯雪梅
Owner 马鹏飞
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap